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Summary
Background Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with 
bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the eﬀ ects of zoledronic 
acid versus clodronic acid in newly diagnosed patients with multiple myeloma. Here, we report the secondary 
outcomes relating to skeletal events.
Methods Patients (≥18 years) with newly diagnosed multiple myeloma were enrolled from 120 centres in the UK and 
received intensive or non-intensive antimyeloma treatment. A computer-generated randomisation sequence was used 
to allocate patients in a 1:1 ratio, through an automated telephone service to intravenous zoledronic acid (4 mg every 
21–28 days) or oral clodronic acid (1600 mg/day), and the drugs were continued at least until disease progression. No 
investigators, staﬀ , or patients were masked to treatment allocation. The primary endpoints—overall survival, 
progression-free survival, and overall response rate—and adverse events have been reported previously. We assessed 
between-group diﬀ erences with Cox proportional hazards models for time to ﬁ rst skeletal-related event and incidence 
of skeletal-related events. These were deﬁ ned as fractures, spinal cord compression, radiation or surgery to bone, and 
new osteolytic lesions. Data were analysed until disease progression. Analyses were by intention to treat. This trial is 
registered, number ISRCTN68454111.
Findings 1960 patients were randomly assigned and analysed—981 in the zoledronic acid group and 979 in the 
clodronic acid group. This trial is fully enrolled, and follow-up continues. At a median follow-up of 
3·7 years (IQR 2·9–4·7), patients in the zoledronic acid group had a lower incidence of skeletal-related events than 
did those in the clodronic acid group (265 [27%] vs 346 [35%], respectively; hazard ratio 0·74, 95% CI 0·62–0·87; 
p=0·0004). Zoledronic acid was also associated with a lower risk of any skeletal-related event in the subsets of patients 
with (233 [35%] of 668 vs 292 [43%] of 682 with clodronic acid; 0·77, 0·65–0·92; p=0·0038) and without bone lesions 
at baseline (29 [10%] of 302 vs 48 [17%] of 276 with clodronic acid; 0·53, 0·33–0·84; p=0·0068). Fewer patients in the 
zoledronic acid group had vertebral fractures than did those in the clodronic acid group (50 [5%] in the zoledronic 
acid group vs 88 [9%] in the clodronic acid group; p=0·0008), other fractures (45 [5%] vs 66 [7%]; p=0·04), and new 
osteolytic lesions (46 [5%] vs 95 [10%]; p<0·0001). 
Interpretation The results of this study support the early use of zoledronic acid rather than clodronic acid in patients 
with newly diagnosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease 
status at baseline.
Funding Medical Research Council (London, UK), Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and 
Ortho Biotech.
Introduction
Multiple myeloma, which is diagnosed in more than 
100 000 people every year,1 is characterised by the growth of 
malignant plasma cells in the bone marrow.2,3 Interactions 
between myeloma cells and bone marrow stromal cells are 
fundamental to the excessive activation and proliferation of 
osteoclasts, causing localised bone destruction.4 Myeloma 
cells also secrete factors that inhibit osteoblasts, blocking 
the repair of osteolytic damage. The resulting bone lesions 
place patients at risk of skeletal-related events5 such as 
pathological fractures, the need for surgery or palliative 
radiation to the bone, and spinal cord compression.6 
Bisphosphonates, such as clodronic acid, pamidronic 
acid, and zoledronic acid, inhibit osteoclast-mediated 
osteolysis and are the pharmacological standard of care 
for patients with myeloma bone disease.4,7,8 Clodronic 
acid reduced skeletal morbidity in an earlier Medical 
Research Council (MRC) study in patients with multiple 
myeloma,9,10 and as a result has become a widely adopted, 
standard treatment in the UK.11 
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In the MRC Myeloma IX trial, we investigated whether 
the addition of an oral (clodronic acid) or an intravenous 
bisphosphonate (zoledronic acid) to antimyeloma treatment 
could improve clinical outcomes in patients with newly 
diagnosed multiple myeloma. Results from this trial 
showed that patients given zoledronic acid had signiﬁ cantly 
improved progression-free survival (hazard ratio [HR] 0·88, 
95% CI 0·80–0·98; p=0·0179) and a reduced risk of death 
(0·84, 0·74–0·96; p=0·0118) versus clodronic acid, with 
overall survival prolonged by 5·5 months.12 Importantly, 
improved overall survival with zoledronic acid remained 
signiﬁ cant after adjustment for the eﬀ ect of skeletal-related 
events (0·85, 0·74–0·97; p=0·018), suggesting that 
zoledronic acid has direct antimyeloma activity. In this 
analysis, we investigated in detail the eﬀ ects of clodronic 
acid and zoledronic acid on skeletal-related events in 
patients with newly diagnosed multiple myeloma.
Methods
Trial design
The MRC Myeloma IX trial was a multicentre (n=120), 
randomised, open-label, two-by-two factorial trial, with 
equal group allocation that was designed to compare 
primary and maintenance treatments and the eﬀ ects of an 
oral (clodronic acid) versus an intravenous bisphosphonate 
(zoledronic acid). Full details have already been reported.12
Patients
Adult patients (≥18 years) with newly diagnosed and 
histologically conﬁ rmed symptomatic multiple myeloma 
were eligible for inclusion in the trial. Patients with 
evidence of bone lesions on axial skeletal survey or fracture 
at baseline were deﬁ ned as having myeloma bone disease. 
Exclusion criteria included previous or concurrent active 
tumours, acute renal failure (deﬁ ned as serum creatinine 
concentration >500 μmol/L that was unresponsive to 72 h 
of rehydration, urine output <400 mL/day, or requirement 
for dialysis), and previous treatment for multiple myeloma 
(except local radiotherapy for bone pain or spinal cord 
compression, bisphosphonates for hypercalcaemia of 
malignancy, or low-dose corticosteroids).
The trial was approved by the North West Multi-centre 
Research Ethics Committee and local review committees 
at all participating centres. All patients provided written 
informed consent.
Randomisation and masking
The methods of randomisation and masking for this 
study have been previously described in detail.12 Brieﬂ y, a 
computer-generated randomisation sequence was used 
to allocate patients in a 1:1 ratio by use of an automated 
telephone service to zoledronic acid or clodronic acid. 
No investigators, staﬀ , or patients were masked to 
treatment allocation.
Treatment
Patients were allocated to two main treatment pathways 
(intensive and non-intensive), as previously described 
in detail.12 In each pathway, patients were randomly 
assigned to oral clodronic acid (1600 mg/day) or 
intravenous zoledronic acid (4 mg, 15 min infusion 
every 3–4 weeks with induction chemotherapy and 
every 4 weeks thereafter). Dose adjustment for patients 
with impaired renal function at baseline and delays in 
administration of the dose in patients with increases in 
serum creatinine concentration during the study were 
implemented for zoledronic acid, per the prescribing 
information. After ﬁ rst-line treatment, eligible patients 
were randomly assigned to maintenance therapy with 
thalidomide (50 mg/day initially, increasing to 
100 mg/day if tolerated) or no thalidomide main-
tenance. Bisphosphonates and maintenance therapy 
were administered continuously at least until 
disease progression.
Oral health recommendations were provided to 
investigators from June, 2006, based on the 
recommendations of Weitzman and colleagues13 to 
reduce the risk of osteonecrosis of the jaw and to identify 
and manage suspected cases of this adverse event.13
1970 patients with newly diagnosed 
multiple myeloma randomly 
assigned to bisphosphonates
1960 analysed (intention-to-treat 
population)
979 clodrononic and CVAD, CTD, 
MP, or CTDa
917 started clodronic acid
11 started zoledronic acid
15 started pamidronic acid
0 started etidronic acid
31 bisphosphonate not initiated
5 bisphosphonate not conﬁrmed
887 started zoledronic acid
25 started clodronic acid
14 started pamidronic acid
1 started etidronic acid
45 bisphosphonate not initiated
9 bisphosphonate not conﬁrmed
981 zoledronic acid and CVAD, CTD, 
MP, or CTDa
820 randomly assigned to thalidomide 
maintenance or watchful waiting
2 excluded
1 no consent
1 withdrew consent
408 thalidomide
195 clodronic acid 213 zoledronic acid
410 no thalidomide
195 clodronic acid 215 zoledronic acid
Figure 1: Trial proﬁ le
The complete trial protocol is provided in Morgan and colleagues.12 CVAD=cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. MP=melphalan and 
prednisolone. CTDa=attenuated CTD.
For full details of the MRC 
Myeloma IX trial see http://ctru.
leeds.ac.uk/myelomaIX 
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Assessments
The incidence and type of adverse events and serious 
adverse events were assessed with continuous monitoring. 
Treatment-emergent serious adverse events were those 
judged by the treating physician to be related to study 
drugs. Serum creatinine concentration was monitored 
every month during induction chemotherapy. After 
induction chemotherapy, the concentration was monitored 
every month for patients in the zoledronic acid group and 
every 3 months for those in the clodronic acid group. Data 
for skeletal-related events, deﬁ ned as vertebral fractures, 
other fractures, spinal cord compression, need for 
radiation or surgery for bone lesions, and new osteolytic 
lesions, were analysed until disease progression. A new 
osteolytic lesion was ﬁ rst recorded as a skeletal-related 
event, and then as disease progression. Indicators of 
skeletal-related events were collected every 3 months. 
These included bone fracture, radiation to bone, surgery 
for bone lesions and spinal cord compression, and height 
loss (as an indicator for further imaging follow-up). Dorsal 
and lumbar spine radiographs were also assessed at 
baseline and every year after the initial randomisation. 
Further imaging was initiated in patients who developed 
clinical symptoms (eg, bone pain) and at disease 
progression. A speciﬁ c case-report form was used to report 
the results of skeletal imaging. Additional prespeciﬁ ed 
analyses of hypercalcaemia of malignancy and exploratory 
analyses of skeletal-related events, excluding the 
development of new osteolytic lesions, were undertaken.
Statistical analysis
The primary endpoints of progression-free survival, 
overall survival, and overall response rate, and the 
secondary endpoint of safety have been reported 
previously.12 Here, we report the secondary endpoint of 
skeletal-related events. The sample size was calculated 
based on the comparison of chemotherapy regimens in 
the factorial design. In the intensive pathway, we aimed 
to recruit 1080 patients (540 per group) to test the 
hypothesis that cyclophosphamide, thalidomide, and 
dexamethasone (CTD) was not inferior to cyclo phos-
phamide, vincristine, doxorubicin, and dexamethasone 
(CVAD), with a hazard ratio of 1·2 and 80% power at a 
5% signiﬁ cance level. In the non-intensive pathway, we 
aimed to recruit 850 patients (425 per group) to assess 
whether attenuated CTD (CTDa) was superior to standard 
chemotherapy with melphalan plus prednisolone, with 
80% power at a 5% signiﬁ cance level. We calculated that 
the sample size for the intensive and non-intensive 
pathways combined had suﬃ  cient power (>80%) to 
detect a reduction of 10% in the proportion of patients 
with skeletal-related events for zoledronic acid compared 
with clodronic acid.
Analyses were based on the treatment that patients 
with histologically conﬁ rmed multiple myeloma who 
provided written informed consent were randomly 
assigned to receive (intention-to-treat population). Time 
to ﬁ rst skeletal-related event (both with and without new 
osteolytic lesions included as a skeletal-related event) was 
assessed by use of a cumulative incidence function.14 
A Cox model for skeletal-related events was generated 
that included the minimisation factors (centre, 
haemoglobin, serum calcium, serum creatinine, and 
platelet count), chemotherapy, and the history of skeletal-
related events at baseline (stratiﬁ ed by pathway). 
Intensive pathway Non-intensive pathway
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
Zoledronic acid
(n=426)
Clodronic acid 
(n=423)
Age (years; median, range) 59 (31–74) 59 (33–78) 73 (59–89) 73 (57–88)
Sex
Female 201 (36%) 218 (39%) 191 (45%) 185 (44%)
Male 354 (64%) 338 (61%) 235 (55%) 238 (56%)
Ethnic origin
White 537 (97%) 534 (96%) 412 (97%) 415 (98%)
Black African 2 (<1%) 8 (1%) 2 (<1%) 2 (<1%)
Black Caribbean 2 (<1%) 5 (<1%) 6 (1%) 1 (<1%)
Chinese 7 (1%) 6 (1%) 1 (<1%) 2 (<1%)
Polynesian 1 (<1%) 0 0 0
Other 6 (1%) 1 (<1%) 3 (<1%) 1 (<1%)
Data not available 0 2 (<1%) 2 (<1%) 2 (<1%)
International Staging System stage
I 129 (23%) 146 (26%) 63 (15%) 47 (11%)
II 198 (36%) 182 (33%) 139 (33%) 173 (41%)
III 174 (31%) 169 (30%) 173 (41%) 160 (38%)
Data not available 54 (10%) 59 (11%) 51 (12%) 43 (10%)
Hyperdiploidy
Yes 159 (29%) 171 (31%) 117 (27%) 132 (31%)
No 133 (24%) 132 (24%) 87 (20%) 76 (18%)
Data not available 263 (47%) 253 (46%) 222 (52%) 215 (51%)
Bone disease
Yes 404 (73%) 411 (74%) 291 (68%) 295 (70%)
No 149 (27%) 138 (25%) 130 (31%) 123 (29%)
Data not available 2 (<1%) 7 (1%) 5 (1%) 5 (1%)
Bone disease or other skeletal-related event
Yes 393 (71%) 406 (73%) 275 (65%) 276 (65%)
No 159 (29%) 141 (25%) 143 (34%) 135 (32%)
Data not available 3 (<1%) 9 (2%) 8 (2%) 12 (3%)
Bone pain
Yes 428 (77%) 415 (75%) 275 (65%) 287 (68%)
No 120 (22%) 132 (24%) 147 (35%) 131 (31%)
Data not available 7 (1%) 9 (2%) 4 (<1%) 5 (1%)
Baseline radiotherapy to bone
Yes 80 (14%) 86 (15%) 43 (10%) 49 (12%)
No 473 (85%) 469 (84%) 382 (90%) 372 (88%)
Data not available 2 (<1%) 1 (<1%) 1 (<1%) 2 (<1%)
Baseline vertebral fractures
Yes 152 (27%) 166 (30%) 114 (27%) 130 (31%)
No 388 (70%) 373 (67%) 302 (71%) 286 (68%)
Data not available 15 (3%) 17 (3%) 10 (2%) 7 (2%)
(Continues on next page)
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Conﬁ rmatory, unadjusted analyses (not reported) were 
also undertaken and provided results similar to the 
adjusted analyses. Relative risks of all on-study skeletal-
related events were assessed with a mean cumulative 
function. To reduce the potential eﬀ ects of related 
skeletal-related events (eg, a fracture requiring surgery) 
in multiple-event analyses, only one skeletal-related event 
per 21 days was included (eg, skeletal-related events of 
possibly linked causality were counted only once, and 
judged to be one skeletal-related event). Post-hoc analyses 
that included all skeletal-related events irrespective of 
whether they were the ﬁ rst or subsequent skeletal-related 
events within 21 days (not reported) were done and 
provided results consistent with those in which the linked 
events were counted as one skeletal-related event. A Cox 
model for all on-study skeletal-related events was 
generated that included the same variables as the Cox 
model for time to ﬁ rst skeletal-related events.15 Statistical 
analysis was done with SAS (version 9.2) and Digital 
Visual Fortran software (version 6.0A). All hypothesis 
tests were two-sided and undertaken at the 5% 
signiﬁ cance level, without adjustment for multiplicity.
This trial is registered, number ISRCTN68454111.
Role of the funding source
No funding organisation was involved in study design, 
data collection, data analysis or interpretation, writing, or 
decision about publication submission. All authors had 
full access to trial data; GJM, JAC, and GHJ had ﬁ nal 
responsibility for the decision to submit for publication.
Results
1970 patients were enrolled between May 14, 2003, and 
Nov 20, 2007, and 1960 were the intention-to-treat 
population (ﬁ gure 1). Baseline demographics and disease 
characteristics of patients were well balanced between 
the zoledronic acid and clodronic acid groups (table 1).12 
1898 (97%) of 1960 patients were white, 1401 (71%) had 
myeloma bone disease at baseline, 562 (29%) had a 
history of vertebral fractures, 231 (12%) had previous 
non-vertebral fractures, 1010 (52%) had been diagnosed 
with osteolytic lesions, and 258 (13%) had previous 
radiotherapy (table 1). Median follow-up was 3·7 years 
(IQR 2·8–4·7) for patients in the zoledronic acid group 
and 3·8 years (2·9–4·7) for those in the clodronic acid 
group; 582 (30%) patients had been given zoledronic acid 
or clodronic acid for at least 2 years (290 [30%] of 981 in 
the zoledronic acid group and 292 [30%] of 979 in the 
clodronic acid group). 
Overall, 611 patients had a skeletal-related event before 
or as the ﬁ rst event of disease progression (eg, new 
osteolytic lesion) during the study. In the overall patient 
population, fewer patients assigned to zoledronic acid 
had a skeletal-related event than did those assigned to 
clodronic acid (265 [27%] of 981 vs 346 [35%] of 979, 
respectively), with zoledronic acid signiﬁ cantly reducing 
the risk of skeletal-related events versus clodronic acid 
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HR 0·74 (95% CI 0·62–0·87); p=0·0004*
HR 0·77 (95% CI 0·65–0·92); 
log-rank p=0·0038
HR 0·53 (95% CI 0·33–0·84); 
log-rank p=0·0068
Clodronic acid
Zoledronic acid
Figure 2: Time to ﬁ rst skeletal-related event overall (A), in patients with bone lesions at baseline (B), and in 
patients without bone lesions at baseline (C)
HR=hazard ratio. *Cox p value.
Intensive pathway Non-intensive pathway
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
Zoledronic acid
(n=426)
Clodronic acid 
(n=423)
(Continued from previous page)
Other baseline fractures
Yes 74 (13%) 73 (13%) 42 (10%) 42 (10%)
No 460 (83%) 460 (83%) 376 (88%) 371 (88%)
Data not available 21 (4%) 23 (4%) 8 (2%) 10 (2%)
Baseline osteolytic lesions
Yes 303 (55%) 293 (53%) 209 (49%) 205 (48%)
No 239 (43%) 247 (44%) 212 (50%) 207 (49%)
Data not available 13 (2%) 16 (3%) 5 (1%) 11 (3%)
Calcium after hydration 
(mmol/L)
Median (IQR) 2·4 (2·2–2·5) 2·4 (2·3–2·5) 2·4 (2·2–2·5) 2·4 (2·3–2·5)
Data not available 37 (7%) 51 (9%) 37 (9%) 37 (9%)
Data are number (%), unless otherwise indicated. Data, in part, from Morgan and colleagues.12 
Table 1: Baseline demographics and disease characteristics of the intention-to-treat population
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(ﬁ gure 2A). Unadjusted analyses provided similar results 
(data not shown). The total number of skeletal-related 
events reported was also lower in the zoledronic acid 
group than in the clodronic acid group (419 vs 597, 
respectively). The proportion of patients with at least one 
skeletal-related event was consistently lower in the 
zoledronic acid group versus the clodronic acid group at 
each timepoint (p<0·0001 overall; table 2). The diﬀ erence 
in incidences of skeletal-related events for zoledronic 
acid versus clodronic acid was signiﬁ cant for each of the 
ﬁ rst 3 years separately, but the total number of skeletal-
related events was low at 48 months and 60 months, and 
reduced the statistical power for the respective 12-month 
comparisons (table 2). Similar distributions of skeletal-
related events were noted for patients treated with 
zoledronic acid and clodronic acid in the intensive 
(zoledronic acid, 155 [28%] of 555; clodronic acid, 
202 [36%] of 556; log-rank p=0·003) and non-intensive 
pathways (zoledronic acid, 110 [26%] of 426; clodronic 
acid, 144 [34%] of 423; log-rank p=0·008). The mean 
skeletal morbidity rate was lower with zoledronic acid 
versus clodronic acid in the intensive and non-intensive 
pathways (0·4 skeletal-related events per patient per year 
vs 0·8 per patient per year, respectively). 
At enrolment, all patients had histologically conﬁ rmed 
symptomatic multiple myeloma. However, patients who 
did not have myeloma bone disease at baseline had lower 
rates of bone pain (248 [43%] of 578 vs 1136 [84%] of 1350), 
and higher rates of anaemia (330 [57%] vs 523 [39%]), renal 
failure (96 [17%] vs 171 [13%]), and infection (74 [13%] vs 
90 [7%]) than did patients with bone disease at baseline.
In an exploratory analysis that excluded new osteolytic 
lesions from the deﬁ nition of skeletal-related event, the 
outcome was similar to the analysis that included new 
osteolytic lesions, and the reduction in risk of skeletal-
related events with zoledronic acid was still signiﬁ cant 
(HR 0·76, 95% CI 0·64–0·89; log-rank p=0·0011). 
Further exploratory analysis by patients’ risk of skeletal-
related events, as identiﬁ ed in another assessment of 
the Myeloma IX patients,16 showed a reduced risk of 
skeletal-related events with zoledronic acid versus 
clodronic acid in the high-risk and low-risk populations 
(data not shown). Analysis by cytogenetic markers (poor 
prognosis deﬁ ned by use of ﬂ uorescence in-situ 
hybridisation [FISH] as adverse IgH translocations, 
gain of 1q, and loss of 17p) showed that the beneﬁ t 
Skeletal-related events Incidence (95% CI) Overall diﬀ erence 
(95% CI) between 
clodronic acid and 
zoledronic acid*
p value for 
preceding 
12 months†
Clodronic acid 
(n=979)
Zoledronic acid 
(n=981)
Clodronic acid 
(n=979)
Zoledronic acid 
(n=981)
12 months 451 (46%) 333 (34%) 0·43 (0·38–0·48) 0·33 (0·28–0·37) 0·11 (0·04–0·18) 0·0002
24 months 93 (9%) 54 (6%) 0·60 (0·53–0·66) 0·42 (0·36–0·48) 0·18 (0·09–0·26) 0·0024
36 months 28 (3%) 16 (2%) 0·69 (0·61–0·78) 0·47 (0·40–0·53) 0·23 (0·12–0·33) 0·0089
48 months 13 (1%) 4 (<1%) 0·80 (0·68–0·91) 0·49 (0·42–0·56) 0·30 (0·17–0·44) 0·0510
60 months 2 (<1%) 2 (<1%) 0·83 (0·70–0·95) 0·51 (0·43–0·58) 0·32 (0·18–0·46) 0·5359
Data are number (%), unless otherwise indicated. *p<0·0001. †Unadjusted p value for the comparison of incidence of skeletal-related events in zoledronic acid group versus 
clodronic acid group per 12 months (eg, 24-month p value is for incidence between 12 months and 24 months).
Table 2: Cumulative annual incidence of ﬁ rst and subsequent skeletal-related events for the intention-to-treat population after randomisation
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Figure 3: Proportion of patients with an on-study skeletal-related event overall (A), with bone lesions at 
baseline (B), and without bone lesions at baseline (C)
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associated with zoledronic acid in terms of skeletal-
related events was attributable to the non-poor prognosis 
subset,16 wherein the beneﬁ ts of zoledronic acid were 
especially meaningful (log-rank p=0·0012; data not 
shown). In the poor-prognosis subset, disease 
progression was fairly rapid, and very few patients were 
assessable for the time to ﬁ rst skeletal-related-event 
endpoint at later timepoints (48 months and 60 months; 
data not shown). 
In an exploratory analysis, patients with osteolytic 
lesions at baseline showed a non-signiﬁ cantly longer 
progression-free survival than did those with no osteolytic 
lesions (20 months, 95% CI 18–21, vs  18 months, 17–19, 
HR 0·90, 0·82–1·00; p=0·0535). However, patients with 
bone disease at baseline had a higher incidence of 
skeletal-related events than did those without bone 
disease at baseline (525 [39%] of 1350 vs 77 [13%] of 578, 
respectively; p<0·0001). Moreover, zoledronic acid, 
compared with clodronic acid, was associated with a 
signiﬁ cantly reduced risk of any skeletal-related event in 
patients with (233 [35%] of 668 vs 292 [43%] of 682; 
ﬁ gure 2B) and without bone disease at baseline (29 [10%] 
of 302 vs 48 [17%] of 276; ﬁ gure 2C). Zoledronic acid was 
associated with a reduced incidence of each type of 
skeletal-related event versus clodronic acid in the overall 
population (ﬁ gure 3A), and signiﬁ cant reductions were 
noted for any skeletal-related event (265 [27%] of 981 vs 
346 [35%] of 979 for clodronic acid; p<0·0001), new 
osteolytic lesions (46 [5%] vs 95 [10%] for clodronic acid; 
p<0·0001), vertebral fractures (50 [5%] vs 88 [9%] for 
clodronic acid; p=0·0008), and other fractures (45 [5%] vs 
66 [7%] for clodronic acid; p=0·04), but not radiotherapy 
(179 [18%] vs 211 [22%] for clodronic acid; p=0·07), surgery 
to the bone (49 [5%] vs 58 [6%] for clodronic acid; p=0·37), 
and spinal-cord compression (13 [1%] vs 19 [2%] for 
clodronic acid; p=0·29). Further details about the other 
fracture sites were not collected during the study. 
Zoledronic acid was associated with a signiﬁ cantly 
reduced incidence of any skeletal-related event in patients 
with (ﬁ gure 3B) and without bone disease at baseline 
(ﬁ gure 3C).
In a prespeciﬁ ed multivariate model of all on-study 
skeletal-related events, the reduction in such events with 
zoledronic acid versus clodronic acid remained signiﬁ cant 
(table 3). Baseline serum calcium concentration, baseline 
skeletal-related event, melphalan plus prednisolone versus 
CTDa (in the non-intensive pathway), and treatment centre 
also showed signiﬁ cant correlations with risk of skeletal-
related events (table 3). Overall, exclusion of new osteolytic 
lesions from the skeletal-related-events composite endpoint 
did not aﬀ ect model outcomes (data not shown).
Results of further exploratory analyses showed that the 
proportion of patients with a skeletal-related event was 
signiﬁ cantly lower with zoledronic acid versus clodronic 
acid when the ﬁ rst 12 months (log-rank p=0·0012) or 
24 months (log-rank p=0·0102) were excluded from the 
analyses (data not shown). Furthermore, signiﬁ cantly 
fewer patients in the zoledronic acid group than in the 
clodronic acid group had at least one skeletal-related 
event after randomisation to maintenance thalidomide 
or no maintenance (log-rank p=0·0005; data not shown). 
The incidences of most adverse events were similar 
in zoledronic acid and clodronic acid groups and have 
been previously reported.12 Overall, the rates of acute 
renal failure were low and similar for patients in the 
zoledronic acid and clodronic acid groups (57 [6%] 
of 983 [two patients for whom conﬁ rmation of consent 
was not received were included in the safety population] 
vs 60 [6%] of 979, respectively; p=0·78). During the 
study, 47 (5%) of 979 patients in the clodronic acid 
group and 43 (4%) of 981 in the zoledronic acid group 
died of renal failure (p=0·67), and 123 (13%) patients in 
the clodronic acid group and 92 (9%) in the zoledronic 
acid group died of multiple myeloma or treatment-
related infections (p=0·025). 28 (3%) patients in the 
clodronic acid group and 28 (3%) in the zoledronic acid 
group had hypercalcaemia, which was reported as a 
serious adverse event in six (<1%) of 979 patients in the 
clodronic acid group and six (<1%) of 983 in the 
zoledronic acid group. As previously reported,12 
conﬁ rmed osteonecrosis of the jaw was rare, but the 
rate was higher in the zoledronic acid group than in the 
clodronic acid group (35 [4%] vs three [<1%], respectively; 
p<0·0001). Gastrointestinal serious adverse events were 
not signiﬁ cantly diﬀ erent with clodronic acid versus 
zoledronic acid (30 [3%] vs 24 [2%], respectively; p=0·41). 
Acute-phase reactions generally were not severe and 
did not interfere with antimyeloma treatments (data 
not shown). 
Treatment-emergent serious adverse events that were 
suspected to be related to bisphosphonate use arose in 41 
(45 events) of 983 patients in the zoledronic acid group 
versus 33 (34 events) of 979 patients in the clodronic acid 
group, and represented a subset of the overall treatment-
emergent serious adverse events that were suspected to be 
Hazard ratio (95% CI) p value
Zoledronic acid vs clodronic acid 0·72 (0·62–0·84) <0·0001
CTD vs CVAD (intensive pathway) 0·91 (0·76–1·10) 0·3399
CTDa vs melphalan+prednisolone (non-intensive pathway) 0·75 (0·60–0·94) 0·0141
Serum calcium concentration (high vs low) 1·31 (1·11–1·55) 0·0012
Serum creatinine concentration (high vs low) 0·93 (0·77–1·12) 0·4362
Haemoglobin concentration (high vs low) 1·08 (0·92–1·26) 0·3489
Platelets (high vs low) 1·19 (0·93–1·53) 0·1623
Skeletal-related events at baseline*
No vs yes 0·35 (0·28–0·44) <0·0001
Missing vs yes 0·83 (0·46–1·52) 0·5532
Centre† ·· <0·0001
CTD=cyclophosphamide, thalidomide, and dexamethasone. CVAD=cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone. CTDa=attenuated CTD. *Any event, including diagnosis of a osteolytic lesion. †Overall p value, but 
not hazard ratio, reported for 120 centres.
Table 3: Multivariate model for risk of skeletal-related events
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related to any of the study drugs as previously reported.12 In 
patients given zoledronic acid, treatment-emergent serious 
adverse events were musculoskeletal, connective tissue, 
and bone disorders (n=16); renal and urinary disorders 
(n=8); haematological disorders (n=5); gastrointestinal 
disorders (dehydration [n=1], nausea and vomiting, 
epigastric tenderness [n=1], and nausea, vomiting, 
constipation, dehydration [n=1]); endocrine, metabolism, 
or nutrition disorders (n=3); infections (n=3); cardiovascular 
disorders (n=2); skin and subcutaneous disorders (n=2); 
ﬂ uid or electrolyte disturbance (n=1); general disorder or 
administration-site condition (n=1); and nervous system 
disorder (n=1). In patients in the clodronic acid group, 
treatment-emergent serious adverse events were 
gastrointestinal disorders (diarrhoea [n=2], abdominal pain 
and bloating [n=1], nausea or vomiting [n=6], oesophagitis 
[n=1], haematemesis [n=1], and gastrointestinal disturbance 
[n=1]); renal and urinary disorders (n=9); infections (n=5); 
haematological disorders (n=2); skin and subcutaneous 
disorders (n=2); cardiovascular disorder (n=1); general 
disorder or administration-site condition (n=1); hepatic 
disorder (n=1); and reproductive system or breast disorder 
(n=1). 
Discussion
The results of the current analysis of the MRC Myeloma 
IX trial show that zoledronic acid was associated with a 
signiﬁ cantly reduced risk of skeletal-related events versus 
clodronic acid in patients with newly diagnosed multiple 
myeloma irrespective of their bone disease status at 
baseline. Additionally, zoledronic acid was associated 
with a reduced incidence of skeletal-related events in the 
intensive and non-intensive pathways, suggesting that all 
patients undergoing initial treatment for multiple 
myeloma could beneﬁ t from early use of zoledronic acid. 
Previous analyses showed that zoledronic acid was 
associated with a signiﬁ cant reduction in the risk of death 
(HR 0·84, 95% CI 0·74–0·96; p=0·0118) and a signiﬁ cant 
improvement in progression-free survival (0·88, 
0·80–0·98; p=0·0179), providing signiﬁ cant clinical 
beneﬁ ts and not just reduction in rates of skeletal-related 
events (panel).12 Although clinical guidelines recommend 
bisphosphonates for patients with documented bone 
lesions,4,7,8,17 all patients (ie, with or without bone disease 
at baseline) could beneﬁ t when bisphosphonates are 
begun early in the course of multiple myeloma. Moreover, 
the reductions in skeletal-related events with zoledronic 
acid versus clodronic acid noted throughout the course of 
the trial support the continued use of zoledronic acid in 
patients with multiple myeloma at least until disease 
progression, when patients went oﬀ  study in this trial 
and data for skeletal-related events were no longer 
collected. However, the optimum duration of zoledronic 
acid is not known, and some patients might beneﬁ t from 
continuing zoledronic acid, possibly at a reduced dose, 
during disease remission. Additional clinical trials are 
needed to further reﬁ ne these aspects of treatment.
In patients with multiple myeloma, renal adverse 
events and osteonecrosis of the jaw are causes for 
concern and should be monitored and managed 
appropriately. In the Myeloma IX trial, adverse events 
were consistent with the established tolerability proﬁ les 
of zoledronic acid and clodronic acid in patients with 
multiple myeloma. Overall, renal adverse events 
occurred at a similar rate for both bisphosphonates 
although clodronic acid is an oral bisphosphonate and 
not typically associated with renal toxicity. Indeed, 
because monitoring the concentrations of creatinine in 
Panel: Research in context
Systematic review
In addition to the experience obtained from previous MRC 
myeloma trials of clodronic acid, a review of the reports 
of clinical trials of a wide variety of combination 
chemotherapy regimens and bisphosphonates was 
undertaken and used to develop the 2×2 factorial trial design 
for the Myeloma IX trial. At the time that the Myeloma IX trial 
was initiated, most patients with symptomatic multiple 
myeloma in the UK were treated long-term with 
bisphosphonates; however, there was no consensus for the 
optimum timing and duration of treatment with 
bisphosphonates, or the eﬃ  cacy for prevention of 
skeletal-related events of all the available bisphosphonates 
and their potential to aﬀ ect disease outcomes and survival 
variables in patients with multiple myeloma. In the Myeloma 
IX trial, we assessed the possible enhanced eﬀ ects on 
disease-related bone changes and survival of a 
third-generation bisphosphonate (zoledronic acid) in 
comparison with a standard older-generation oral agent 
(clodronic acid).
Interpretation
The results of the Myeloma IX trial showed signiﬁ cant 
beneﬁ ts with zoledronic acid versus clodronic acid on 
progression-free survival, overall survival, and several 
variables for skeletal-related events, and, to our knowledge, 
for the ﬁ rst time established the superiority of one 
bisphosphonate over another in patients with multiple 
myeloma. Moreover, exploratory analyses have shown 
signiﬁ cant beneﬁ ts with treatment before the onset of bone 
lesions and also with long-term treatment (eg, during 
maintenance therapy or long-term follow-up). The data from 
Myeloma IX provide compelling evidence that zoledronic acid 
should be considered an essential component of therapeutic 
regimens for patients starting treatment for newly diagnosed 
multiple myeloma irrespective of whether bone lesions are 
already present, and support the continuation of zoledronic 
acid at least until disease progression. However, the results 
of this study do not provide insight into whether the 
frequency of dosing with zoledronic acid can be reduced after 
initial treatment, such as in patients with long-term 
remission of their disease.
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the serum was less frequent for the clodronic acid group 
than for the zoledronic acid group (ie, every 3 months vs 
monthly, respectively), any observation bias would be in 
favour of clodronic acid. This bias suggests that the 
renal adverse events reported in the Myeloma IX trial 
were most likely a result of the disease, antimyeloma 
treatments, non-myeloma-related drugs, or other 
comorbidities rather than toxicity associated with 
bisphosphonates, validating the renal safety protocols 
for zoledronic acid. Although osteonecrosis of the jaw 
arose at a higher rate in patients in the zoledronic acid 
group, most events were low grade (as deﬁ ned by 
Weitzman and colleagues13) and manageable. 
Recommendations for prevention and management of 
osteonecrosis of the jaw were implemented in Myeloma 
IX from June, 2006, onwards,13 but further reductions in 
the risk of osteonecrosis of the jaw might be possible 
with prevention strategies that were reported 
subsequently. Recent evidence suggests that the risk of 
osteonecrosis of the jaw can be signiﬁ cantly reduced by 
the implementation of preventative dental care, most 
cases are manageable, and complete healing of lesions 
of osteonecrosis of the jaw is possible.18 Although a 
small percentage of patients in the zoledronic acid 
group were reported to have adverse events that were 
consistent with acute-phase reactions (ie, fever 
unattributed to infection, myalgia, and arthralgia), these 
did not lead to discontinuation or delay in antimyeloma 
treatments. The results of a study in postmenopausal 
women (n=7765) given intravenous zoledronic acid 
(5 mg per year) for osteoporosis showed that the acute-
phase reaction lasted about 3 days and the incidence 
was similar to that with placebo by the third infusion.19 
In Myeloma IX, acute-phase reactions, which are 
thought to result from immune-cell activation after the 
ﬁ rst infusion of zoledronic acid, might have been less 
frequent than in the postmenopausal osteoporosis 
setting because of the fairly high prevalence of disease 
and treatment-related myelosuppression in patients 
with multiple myeloma. Gastrointestinal adverse events 
are generally more common in patients given oral 
bisphosphonates, as noted here—gastrointestinal treat-
ment-emergent serious adverse events arose more 
frequently with clodronic acid than with zoledronic acid 
(12 vs three events, respectively). 
Skeletal-related events are serious, potentially 
debilitating complications aﬀ ecting most patients with 
multiple myeloma, especially those who do not receive 
bone-targeted therapy.6 Bisphosphonates can eﬀ ectively 
reduce the risk of skeletal-related events in this 
population.20–22 Consequently, clinical practice guidelines 
and recommendations include bisphosphonates as a key 
component of disease treatment for patients with 
myeloma bone disease.4,7–8,17 In the previous MRC 
Myeloma studies,9,10 clodronic acid was of particular 
beneﬁ t (ie, slowing progression of skeletal disease and 
reducing skeletal morbidity) to patients without bone 
lesions at treatment initiation.9,10 Moreover, subgroup 
analysis suggested that clodronic acid might confer 
survival beneﬁ ts in patients without overt bone disease 
at diagnosis.10 
Three bisphosphonates have been approved for 
patients with osteolytic bone lesions from multiple 
myeloma—zoledronic acid and pamidronic acid in the 
USA and Europe, and clodronic acid in Europe. Previous 
comparison of zoledronic acid with pamidronic acid in 
patients with multiple myeloma showed no signiﬁ cant 
diﬀ erence in the incidence of skeletal-related events 
(86 [47%] of 183 vs 82 [49%] of 167, respectively),20 or the 
time to ﬁ rst skeletal-related event (380 days vs 286 days, 
respectively; p=0·538) among patients with multiple 
myeloma and established osteolytic lesions.21 The 
more recently introduced nitrogen-containing bisphos-
phonates, pamidronic acid and zoledronic acid, are 
more potent inhibitors of osteoclastic activity than are 
the earlier, non-nitrogen-containing bisphosphonates 
(eg, clodronic acid).23 However, pamidronic acid is more 
similar to clodronic acid in terms of antiresorptive 
potency than it is to zoledronic acid, which has more 
potent anticancer eﬀ ects in preclinical models of 
myeloma and other cancers.23–25 Because of the short 
infusion time and particular antiresorptive potency of 
zoledronic acid compared with pamidronic acid—
conﬁ rmed in preclinical and clinical investigations—it 
was adopted as the comparator for clodronic acid, a UK 
standard, in the Myeloma IX Trial. Whether pamidronic 
acid would have provided similar reductions in skeletal-
related events versus clodronic acid in this patient 
population is not known. Treatment regimens for 
multiple myeloma also changed between the completion 
of the trial of zoledronic acid versus pamidronic acid,21 
and the start of the Myeloma IX trial.
Induction chemotherapy regimens used to treat 
patients with multiple myeloma are continually evolving 
as new drugs and new combinations are assessed in 
clinical trials. For example, the antimyeloma regimens 
used in the Myeloma IX trial included drugs that are now 
being combined with newer agents such as bortezomib. 
In recent years, there has been interest in the potential 
for immunomodulatory drugs (eg, lenalidomide) and 
bortezomib to slow osteolytic bone destruction in 
multiple myeloma through inhibition of osteoclast 
activity, and increased osteoblast activity (eg, 
bortezomib).26–30 So far, these data are derived from 
preclinical studies and clinical assessments of 
biochemical markers of bone resorption and bone 
mineral density and have not yet been correlated with a 
reduction in the risk of skeletal-related events. There is 
no evidence to suggest that antimyeloma treatment alone 
can replace bisphosphonates for treatment of multiple 
myeloma bone disease; however, the potential for 
synergistic eﬀ ects between these drugs and 
bisphosphonates is intriguing. On the basis of the data 
for skeletal-related events obtained in this study, 
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zoledronic acid is very likely to provide clinically 
signiﬁ cant beneﬁ ts in combination with newer 
antimyeloma regimens because it has proved beneﬁ cial 
in the prevention of skeletal-related events in patients 
with solid tumours who were given a broad range of 
primary anticancer treatments.21,31,32 However, clinical 
studies are needed to conﬁ rm this theory. 
The Myeloma IX study is the ﬁ rst large, independent 
clinical trial in patients with newly diagnosed multiple 
myeloma, and its results show unequivocal superiority 
of one bisphosphonate over another for reduction of the 
risk of skeletal-related events. Overall, the data from this 
study support the early use of zoledronic acid for 
reduction in the risk of skeletal-related events in all 
patients with newly diagnosed multiple myeloma.
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